Disclosure of the Dealings Between Drug Developing Companies and the FDA Under the Federal Securities Laws
DSpace/Manakin Repository
- DASH Home
- Harvard Law School
- HLS Student Papers
- View Item
Disclosure of the Dealings Between Drug Developing Companies and the FDA Under the Federal Securities Laws
| Title: | Disclosure of the Dealings Between Drug Developing Companies and the FDA Under the Federal Securities Laws |
| Author: | Heinonen, Mikko |
| Citation: | Disclosure of the Dealings Between Drug Developing Companies and the FDA Under the Federal Securities Laws (2002 Third Year Paper) |
| Full Text & Related Files: |
Heinonen.pdf (0bytes; PDF) 
Heinonen.rtf (244.2Kb; RTF file) 
Heinonen.html (204.2Kb; HTML)
|
| Abstract: | The purpose of this article is to highlight the main issues raised by the Food and Drug Administration’s (“FDAâ€) approval process relating to new drugs and the treatment of this process receives in the context of the Federal Securities Laws . The partial inspiration for this article has been the recent highly publicized case concerning ImClone Systems Incorporated – a case, which well exemplifies both the connection between the valuation of a biotech/medical company and the FDA’s approval process for new drugs, and also the huge effect of the approval process to the market’s valuation of the stock price. |
| Terms of Use: | This article is made available under the terms and conditions applicable to Other Posted Material, as set forth at http://nrs.harvard.edu/urn-3:HUL.InstRepos:dash.current.terms-of-use#LAA |
| Citable link to this page: | http://nrs.harvard.edu/urn-3:HUL.InstRepos:8852181 |
This item appears in the following Collection(s)
-
HLS Student Papers [559]
HLS Student Papers
Contact administrator regarding this item (to report mistakes or request changes)
